Dai Maruyama, Shinsuke Iida, Ryunosuke Machida, Shigeru Kusumoto, Noriko Fukuhara, Nobuhiko Yamauchi, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, et al. Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer science. 2022. 113. 9. 3267-3270
Yoshinari Endo, Yusuke Inoue, Masato Karayama, Yasuyuki Nagata, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, et al. Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report. JTO clinical and research reports. 2022. 3. 1. 100263-100263
Ibuki Takatsuka, Hiroya Hirata, Takumi Takahashi, Satoshi Dohtan, Shinichiro Oka, Nami Sakamoto, Masamitsu Takaba, Miwa Adachi, Tomonari Takemura, Yasuyuki Nagata, et al. Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase. Leukemia research reports. 2022. 17. 100312-100312
Miwa Adachi, Daisuke Yokota, Hiroya Hirata, Katsumi Koyauchi, Satoshi Dohtan, Shinichiro Oka, Nami Sakamoto, Masamitsu Takaba, Tomonari Takemura, Yasuyuki Nagata, et al. Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation. International journal of hematology. 2021. 114. 2. 252-262
Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, Masaki Ri, Yasuyuki Nagata, Hiroshi Kosugi, Yoshimitsu Shimomura, Ichiro Hanamura, Shigeo Fuji, Koichiro Minauchi, et al. Expression of activated integrin β7 in multiple myeloma patients. International journal of hematology. 2021. 114. 1. 3-7
Yasuyuki Nagata, Itsuko Ishizaki, Michihiko Waki, Yoshimi Ide, Md Amir Hossen, Kazunori Ohnishi, Mitsutoshi Setou. Palmitic acid as an anti-multiple myeloma molecule was sorted out from lipid profiling by secondary ion mass spectrometry. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2015. 15. S238-S238
Yasuyuki Nagata, Itsuko Ishizaki, Michihiko Waki, Yoshimi Ide, Amir Hossen, Kazunori Ohnishi, Mitsutoshi Setou. Palmitic Acid, As Verified Using Lipid Profiling By Secondary Ion Mass Spectrometry, Demonstrates Anti-Tumor Activity Against Multiple Myeloma. BLOOD. 2014. 124. 21